A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV‐HIV Co‐infected Adults in North America. Issue 3 (25th August 2021)

• Record Type: Journal Article
• Authors: Sterling, Richard K.; King, Wendy C.; Khalili, Mandana; Chung, Raymond T.; Sulkowski, Mark; Jain, Mamta K.; Lisker‐Melman, Mauricio; Ghany, Marc G.; Wong, David K.; Hinerman, Amanda S.; Bhan, Atul K.; Wahed, Abdus S.; Kleiner, David E.
• Is Part Of: Hepatology. Volume 74:Issue 3(2021)
• Page Start: 1174
• Page End: 1189
• Publication Date: 2021-08-25
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.31823
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Background and Aims: Histological and clinical outcomes in HBV‐HIV coinfection in the era of combination antiretroviral therapy (cART) are poorly defined. Approach and Results: Adult patients co‐infected with HBV‐HIV from eight North American sites were enrolled in this National Institutes of Health (NIH)–funded prospective observational study (n = 139). Demographic, clinical, serological, and virological data were collected at entry and every 24 weeks for ≤ 192 weeks. Paired liver biopsies were obtained at study entry and at ≥ 3 years of follow‐up. Biopsies were assessed by a central pathology committee using the modified Ishak scoring system. Clinical outcome rate and changes in histology are reported. Among participants with follow‐up data (n = 114), median age was 49 years, 91% were male, 51% were non‐Hispanic Black, and 13% had at‐risk alcohol use, with a median infection of 20 years. At entry, 95% were on anti‐HBV cART. Median CD4 count was 562 cells/mm 3 and 93% had HIV < 400 copies/mL. HBeAg was positive in 61%, and HBV DNA was below the limit of quantification (< 20 IU/mL) in 61% and < 1, 000 IU/mL in 80%. Clinical events were uncommon across follow‐up: one hepatic decompensation, two HCC, no liver transplants, and one HBV‐related deaths, with a composite endpoint rate of 0.61/100 person‐years. Incident cirrhosis (n = 1), alanine aminotransferase flare (n = 2), and HBeAg loss (n = 13) rates were 0.40, 0.65, and 6.86 per 100 person‐years, respectively. No participants had HBsAg loss. Paired biopsy (n = 62; median 3.6 years apart) revealed minimal improvement in Histologic Activity Index (median [interquartile range]: 3 [2‐4] to 3 [1‐3]; P = 0.02) and no significant change in fibrosis score (1 [1‐2] to 1 [0‐3]; P = 0.58). Conclusions: In a North American cohort of adults with HBV‐HIV on cART with virological suppression, clinical outcomes and worsening histological disease were uncommon.